Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH2 | P48735 | 14/20 | 0.70 |
| ▸ | IDH1 | O75874 | 13/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.64 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.64 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.64 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.64 |
| ▸ | KDR | P35968 | 1/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18557150 | 0.86 | IDH2 (0.76) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| SCHEMBL28565595 | 0.86 | IDH1 (0.76) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| SCHEMBL20210919 | 0.84 | IDH2 (0.60) | IDH2IDH1 | |
| SCHEMBL24754739 | 0.84 | IDH2 (0.72) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| SCHEMBL28568751 | 0.83 | IDH2 (0.65) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| SCHEMBL29763239 | 0.83 | IDH2 (0.71) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| SCHEMBL29763396 | 0.83 | IDH2 (0.71) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| SCHEMBL15124311 | 0.83 | IDH2 (0.71) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| SCHEMBL15094940 | 0.83 | IDH2 (0.71) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| SCHEMBL20210918 | 0.81 | IDH1 (0.79) | IDH2IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3330258-B1 | 1, 3, 5-TRIAZINE DERIVATIVE AND METHOD OF USING SAME | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2021-07-14 | — | — | EP | disclosed |
| EP-3330258-B1 | 1, 3, 5-TRIAZINE DERIVATIVE AND METHOD OF USING SAME | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2021-07-14 | — | — | EP | disclosed |
| US-10745383-B2 | 1,3,5-triazine derivative and method of using same | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-08-18 | — | — | US | disclosed |
| US-10745383-B2 | 1,3,5-triazine derivative and method of using same | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-08-18 | — | — | US | disclosed |
| US-10654826-B2 | — | — | 2020-05-19 | — | — | US | disclosed |
| US-10654826-B2 | — | — | 2020-05-19 | — | — | US | disclosed |
| EP-3330258-A1 | 1, 3, 5-TRIAZINE DERIVATIVE AND METHOD OF USING SAME | Chia Tai Tianqing Pharmaceutical Group Co.,Ltd (CN) | 2018-06-06 | — | — | EP | disclosed |
| EP-3330258-A1 | 1, 3, 5-TRIAZINE DERIVATIVE AND METHOD OF USING SAME | Chia Tai Tianqing Pharmaceutical Group Co.,Ltd (CN) | 2018-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10745383-B2 | 1,3,5-triazine derivative and method of using same | IDH2, IDH3A, IDH1 | IDH2 1/4885IDH1 3/4885ABCB11 2009/4885 |
| US-10654826-B2 | — | IDH2, IDH1, IDH3A | IDH2 1/4885IDH1 2/4885ABCB11 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.